Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01852370 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases

Study acronym: BOLT+BMT
StatusEnrolling by Invitation
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Nov 2025 to Nov 2026
    • Study completion date: Nov 2026 to Nov 2027
    v19
  2. 2 versions Re-verified since Nov 22, 2024, no change to tracked fieldsv17-v18
  3. Primary completion date: Nov 2023 to Nov 2025
    • Study completion date: Nov 2024 to Nov 2026
    v16
  4. 3 versions Re-verified since Dec 15, 2020, no change to tracked fieldsv13-v15
  5. Primary completion date: Dec 2019 to Nov 2023
    • Study completion date: Dec 2021 to Nov 2024
    v12
Show 10 earlier versionsHide 10 earlier versions
  1. Secondary endpoints revised (14)v11
  2. Trial status: Recruiting to Enrolling by Invitation
    • Primary completion date: Jun 2019 to Dec 2019
    • Study completion date: Aug 2022 to Dec 2021
    • Site details revised
    v10
  3. Lead sponsor: University of Pittsburgh to Paul Szabolcsv9 Show 4 more changesShow less
    • Primary endpoints: 5 to 8
    • Start date: Jun 2013 to Jun 20, 2013
    • Eligibility criteria expanded, about 323 words
    • Secondary endpoints: 5 to 14
  4. Re-verified, no change to tracked fieldsv8
  5. Site contact updatedv7
  6. 3 versions Re-verified since Aug 19, 2013, no change to tracked fieldsv4-v6
  7. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  8. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Paul Szabolcs
9 trials monitored
See 2 trials at risk
The purpose of this study is to determine whether bilateral orthotopic lung transplantation (BOLT) followed by cadaveric partially-matched hematopoietic stem cell transplantation (HSCT) is safe and effective for patients aged 5-45 years with primary immunodeficiency (PID) and end-stage lung disease.
Trial Details
NCT Number NCT01852370
Lead Sponsor Paul Szabolcs
Conditions
(from sponsor)		 Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified, Severe Chronic Neutropenia, Chronic Granulomatous Disease (CGD), Hyper IgE Syndromes, Hyper IgM Deficiencies, Wiskott-Aldrich Syndrome, Mendelian Susceptibility to Mycobacterial Disease +1 more
Related terms Common Variable Immunodeficiency, Granulomatous Disease, Chronic, Job Syndrome, Neutropenia, severe chronic, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov